Lisa Karimi-Naser
Nucleus Biologics

I could not find a consistent reagent for reliable immune cell culture.

I have over a decade of experience in immunology and inflammation research. This experience in the biotechnology industry has routinely proven one thing: Research requires consistency – particularly research for immunotherapies.

While at Novo Nordisk, I studied disrupting pathways in T cell interactions involved in autoinflammatory diseases. More recently at Synthetic Genomics, I used CRISPR/Cas9 to modify primary cells and induced pluripotent stem cells (iPSC) with the goal of pig-to-human xenotransplantation. I studied how T cells respond to genetic modification because immune response modulation on both sides is essential in achieving successful cross-species organ transplantation.

Immune cells can be highly reactive to foreign antigens. Thus, these sensitive systems demand consistent reagents. I frequently wasted hours testing reagents from different lots and companies only to find that most suffered from high variability.

I found a company who offered a novel AND reproducible product driven by their supply chain.

I first encountered Nucleus Biologics while working at Synthetic Genomics. I conducted a study testing multiple lots of their single-origin FBS product and found unprecedented lot-to-lot consistency in our primary T cell system. I had never experienced this level of reproducibility with any other company in the industry.

These results were very compelling. FBS consistency ensured my media would function reliably over the course of my research – regardless of whether I had to switch lots mid-project – and gave me confidence in the integrity of my data. This level of reproducibility is paramount when working with two distinct immune systems and sensitive cell types. Not only would this decrease time spent looking at different lots and repeating assays, but it would increase the credibility of my research. Reproducible results would ultimately make my work more relevant to other researchers.

Their attention to consistency is one of the reasons I chose to start working for Nucleus Biologics.

I designed an experiment doomed to fail and was floored by the results.

After I started working at Nucleus Biologics, I decided to run a rigorous variant of my previous experiment. I focused my efforts on the difference between heat inactivated serum and unaltered serum while also increasing the number of lots. I designed an extensive experiment to account for a myriad of factors. As your stereotypical cynical scientist, I was skeptical that the product would hold up to this scrutiny.

To say the least, I was shocked by these results. This figure below is an example of my data:

This level of product integrity is something I hadn’t seen in all of my years in the industry. Nucleus Biologics is truly enhancing the research experience for scientists like myself. Working with our quality reagents could reduce time from research to clinic, saving valuable resources, energy, and money.

To see my full experimental methods and results, download the application note:

Application Note: The Importance of Lot-to-Lot Consistency PDF


Download the full application note

About the Author

Lisa Naser is a Research Scientist and Head of Manufacturing at Nucleus Biologics. She received her Bachelor of Science degree in Biology from the University of Washington and has since worked in the biotechnology industry for more than a decade.

Get exclusive updates direct to your inbox.